Company
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 18 of 38
The bank said while the pharma firm saw the separation as an “opportunity to reset its debt” there were also questions about what would happen to its dividend
The results came from the first study of long-acting injectable therapy for HIV prevention among women
The broker sees structural risks from mergers and acquisitions and dividend uncertainty before the consumer spin out in 2022
The pharma company noted the increasing scientific evidence shows that climate issues affect human health
Analysts said the pharma company is undervalued in its prospects for growth
Revenues overall fell by 8% to £8.65bn, while operating profits dropped 13% to £1.87bn.
The two companies have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility
Archive
The pharmaceutical giant will likely be eyed for any news on vaccination rates to help drive earnings, while retailer Next will be watched as a possible bellwether for the health of the wider UK retail sector
A look at the week's major news regarding the pandemic
The final trial is planned to start in December if data from the current one can support it
BLENREP is the fifth major medicine approval for GSK and the second from its oncology portfolio
A Phase 1/ 2 study is expected to start in September, followed by a Phase 3 study by the end of 2020
A round-up of Friday's major news regarding the pandemic
Over US$1bn are needed to support the jab’s development such as the trials on humans
There was a sharp drop off in the second quarter as disruption from COVID-19 began to be felt
Britain is to buy 60mln doses of the inoculation, which has yet to enter the clinic
President Trump was reported to have offered to pay for exclusive access to CureVac's COVID-19 vaccine
Analysts at Liberum see peak sales of £3.8bn if the drug is approved
The pharma giant is identifying potential vaccines that could be suitable to use the agent
Injectable cabotegravir is 69% more effective than daily tablets of emtricitabine/tenofovir disoproxil fumarate, the current standard of care
